The Truth about Using Medical Marijuana and Cannabis in Treating Autism (original) (raw)
Related papers
MEDICINAL USE OF CANNABIS SATIVA FOR THE TREATMENT OF AUTISM (Atena Editora)
MEDICINAL USE OF CANNABIS SATIVA FOR THE TREATMENT OF AUTISM (Atena Editora), 2023
Cannabis Sativa is a plant with medicinal capacity, its function is to improve patients with different diseases, and is widely used in its oily form to treat fibromyalgia and seizures as the plant has the ability to reduce the number of seizures. Autism is a disorder that has no cure, only treatment, which is medication and not medication, such as therapies. People with ASD, an autism spectrum disorder, can have numerous characteristics such as stereotyping and even seizures. Cannabidiol is a substance derived from Marijuana that does not have its hallucinogenic principle, which is the active ingredient that causes hallucinations and the effects described when using the drug illegally, this substance is known as CBD and has been studied over the years, one of his studies are applied to the treatment of autism symptoms, in this article we will analyze through a bibliographical review the studies of this case and the effects that Cannabidiol generated in patients with ASD.
Cannabinoid treatment for autism: a proof-of-concept randomized trial
Molecular Autism
Background Endocannabinoid dysfunction in animal models of autism spectrum disorder (ASD) and accumulating, albeit anecdotal, evidence for efficacy in humans motivated this placebo-controlled double-blind comparison of two oral cannabinoid solutions in 150 participants (age 5–21 years) with ASD. Methods We tested (1) BOL-DP-O-01-W, a whole-plant cannabis extract containing cannabidiol and Δ9-tetrahydrocannabinol at a 20:1 ratio and (2) BOL-DP-O-01, purified cannabidiol and Δ9-tetrahydrocannabinol at the same ratio. Participants (N = 150) received either placebo or cannabinoids for 12-weeks (testing efficacy) followed by a 4-week washout and predetermined cross-over for another 12 weeks to further assess tolerability. Registered primary efficacy outcome measures were improvement in behavioral problems (differences between whole-plant extract and placebo) on the Home Situation Questionnaire-ASD (HSQ-ASD) and the Clinical Global Impression-Improvement scale with disruptive behavior anc...
Journal of Medical Case Reports
Background The pharmacological treatment for autism spectrum disorders is often poorly tolerated and has traditionally targeted associated conditions, with limited benefit for the core social deficits. We describe the novel use of a cannabidiol-based extract that incidentally improved core social deficits and overall functioning in a patient with autism spectrum disorder, at a lower dose than has been previously reported in autism spectrum disorder. Case presentation The parents of a 15-year-old boy, of South African descent, with autism spectrum disorder, selective mutism, anxiety, and controlled epilepsy, consulted a medical cannabis physician to trial cannabis extract to replace seizure medications. Incidentally, at a very low cannabidiol-based extract dose, he experienced unanticipated positive effects on behavioral symptoms and core social deficits. Conclusion This case report provides evidence that a lower than previously reported dose of a phytocannabinoid in the form of a ca...